QQ客服 官方微博 反馈留言

	Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer
	Chen, Xue-Lian; Du, Feng; Hong, Ruo-Xi; Wang, Jia-Yu; Luo, Yang; Li, Qing; Fan, Ying; Xu, Bing-He
	2016
卷号	35页码:39
关键词	Hormonal therapy Maintenance capecitabine monotherapy First-line capecitabine-based combination chemotherapy Metastatic breast cancer
ISSN号	1000-467X
DOI	10.1186/s40880-016-0101-7
URL标识	查看原文
收录类别	SCIE ; PUBMED ; ISTIC
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6383052
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Chen, Xue-Lian,Du, Feng,Hong, Ruo-Xi,et al. Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer[J],2016,35:39.
APA	Chen, Xue-Lian.,Du, Feng.,Hong, Ruo-Xi.,Wang, Jia-Yu.,Luo, Yang.,...&Xu, Bing-He.(2016).Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer.,35,39.
MLA	Chen, Xue-Lian,et al."Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer".35(2016):39.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。